Patents by Inventor Murray Ratcliffe

Murray Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20010018065
    Abstract: This invention relates to the treatment of diarrhea and related conditions caused by pathogenic E. coli infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the shiga like toxins (SLT) produced by pathogenic E. coli whenever an antibiotic is administered, improved treatment is provided. Novel compositions containing both antibiotic and toxin binding composition and methods of treatment which use simultaneous administration toxin binding composition whenever antibiotic is administered are provided. These compositions and methods kill the enteric E. coli organisms which produce the conditions and neutralize the SLT produced by the organisms and/or released from the organisms when they are killed. Thus, these compositions and methods are better able to ameliorate the symptoms of the infection and inhibit progression of this infection into hemolytic uremic syndrome (HUS) than conventional treatment.
    Type: Application
    Filed: March 15, 2001
    Publication date: August 30, 2001
    Inventors: David John Rafter, Robert Murray Ratcliffe, Bradley G. Thompson, Glen D. Armstrong
  • Patent number: 6224891
    Abstract: This invention relates to the treatment of diarrhea and related conditions caused by pathogenic E. coli infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the shiga like toxins (SLT) produced by pathogenic E. coli whenever an antibiotic is administered, improved treatment is provided. Novel compositions containing both antibiotic and toxin binding composition and methods of treatment which use simultaneous administration toxin binding composition whenever antibiotic is administered are provided. These compositions and methods kill the enteric E. coli organisms which produce the conditions and neutralize the SLT produced by the organisms and/or released from the organisms when they are killed. Thus, these compositions and methods are better able to ameliorate the symptoms of the infection and inhibit progression of this infection into hemolytic uremic syndrome (HUS) than conventional treatment.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: May 1, 2001
    Assignee: Synsorb Biotech, Inc.
    Inventors: David John Rafter, Robert Murray Ratcliffe, Bradley G. Thompson, Glen D. Armstrong
  • Patent number: 6030815
    Abstract: The present invention provides improved methods for the preparation of sialyl galactosides. The methods use sialyl transferase cycle in which the reaction conditions are optimized to provide increased yields.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: February 29, 2000
    Assignee: Neose Technologies, Inc.
    Inventors: Shawn DeFrees, Robert J. Bayer, Murray Ratcliffe
  • Patent number: 5922577
    Abstract: The present invention provides improved methods for the formation of glycosidic linkages. These methods are useful for the preparation of compounds of formula:NeuAc.alpha.(2.fwdarw.3)Gal.beta.(1.fwdarw.4)(Fuc.alpha. 1.fwdarw.3)GlcN(R').beta.(1.fwdarw.3)Gal.beta.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: July 13, 1999
    Assignee: Cytel Corporation
    Inventors: Shawn Defrees, Robert J. Bayer, Murray Ratcliffe
  • Patent number: 5876980
    Abstract: The present invention provides improved methods for the preparation of sialyl galactosides. The methods use sialyl transferase cycle in which the reaction conditions are optimized to provide increased yields.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: March 2, 1999
    Assignee: Cytel Corporation
    Inventors: Shawn DeFrees, Robert J. Bayer, Murray Ratcliffe
  • Patent number: 5728554
    Abstract: The present invention provides improved methods for the formation of glycosidic linkages. These methods are useful for the preparation of compounds of formula:NeuAc.alpha.(2.fwdarw.3)Gal.beta.(1.fwdarw.4)(Fuc.alpha. 1.fwdarw.3)GlcN(R').beta.(1.fwdarw.3)Gal.beta.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: March 17, 1998
    Assignee: Cytel Corporation
    Inventors: Robert J. Bayer, Shawn DeFrees, Murray Ratcliffe
  • Patent number: 4362720
    Abstract: O-acetylated glycals react with ceric ammonium nitrate in the presence of sodium azide to provide, in good yield, O-acetylated 2-azido-2-deoxy glycosyl nitrates. These nitrates can be used to prepare 2-amino-2-deoxy sugars, such as D-galactosamine and lactosamine. The O-acetylated 2-azido-2-deoxy glycosyl nitrates can alternately be converted to O-acetylated 2-azido-2-deoxy glycosyl halides which are useful in the preparation of O-acetylated 2-azido-2-deoxy glycosides, which in turn can be reduced to 2-amino-2-deoxy glycosides. Of particular interest are the syntheses of 2-amino-2-deoxy glycosides which correspond to the terminal units of the antigenic determinant for the human A blood group. Attachment of these glycosides to a solid support provides immunoabsorbents which efficiently and preferentially absorb anti-A antibodies from blood plasma.
    Type: Grant
    Filed: September 19, 1979
    Date of Patent: December 7, 1982
    Assignee: Chembiomed Ltd.
    Inventors: Raymond U. Lemieux, R. Murray Ratcliffe
  • Patent number: 4308376
    Abstract: O-acetylated glycals react with ceric ammonium nitrate in the presence of sodium azide to provide, in good yield, O-acetylated 2-azido-2-deoxy glycosyl nitrates. These nitrates can be used to prepare 2-amino-2-deoxy sugars, such as D-galactosamine and lactosamine. The O-acetylated 2-azido-2-deoxy glycosyl nitrates can alternately be converted to O-acetylated 2-azido-2-deoxy glycosyl halides which are useful in the preparation of O-acetylated 2-azido-2-deoxy glycosides, which in turn can be reduced to 2-amino-2-deoxy glycosides. Of particular interest are the syntheses of 2-amino-2-deoxy glycosides which correspond to the terminal units of the antigenic determinant for the human A blood group. Attachment of these glycosides to a solid support provides immunoabsorbents which efficiently and preferentially absorb anti-A antibodies from blood plasma.
    Type: Grant
    Filed: September 19, 1979
    Date of Patent: December 29, 1981
    Assignee: Chembiomed Ltd.
    Inventors: Raymond U. Lemieux, R. Murray Ratcliffe
  • Patent number: 4195174
    Abstract: O-acetylated glycals react with ceric ammonium nitrate in the presence of sodium azide to provide, in good yield, O-acetylated 2-azido-2-deoxy glycosyl nitrates. These nitrates can be used to prepare 2-amino-2-deoxy sugars, such as D-galactosamine and lactosamine. The O-acetylated 2-azido-2-deoxy glycosyl nitrates can alternately be converted to O-acetylated 2-azido-2-deoxy glycosyl halides which are useful in the preparation of O-acetylated 2-azido-2-deoxy glycosides, which in turn can be reduced to 2-amino-2-deoxy glycosides. Of particular interest are the syntheses of 2-amino-2-deoxy glycosides which correspond to the terminal units of the antigenic determinant for the human A blood group. Attachment of these glycosides to a solid support provides immunoabsorbents which efficiently and preferentially absorb anti-A antibodies from blood plasma.
    Type: Grant
    Filed: April 7, 1978
    Date of Patent: March 25, 1980
    Assignee: Chembiomed Ltd.
    Inventors: Raymond U. Lemieux, R. Murray Ratcliffe